Conventional synthetic DMARDs, such as methotrexate, hydroxychloroquine, and sulfasalazine, and bDMARDs, such as TNF-α and IL-6 inhibitors, may be necessary in patients with moderate to severe arthritis that is refractory to glucocorticoid therapy [77]. This evidence concerns the gene TNF and Arthritis.